Global Extramammary Paget Disease Market –Global Industry Trends & Forecast to 2029
The Extramammary Paget disease market was valued at USD 204.41 million in 2021 and is expected to reach USD 308.98 million by 2029, registering a CAGR of 5.30% during the forecast period of 2022 to 2029.
Extramammary Paget
Disease Market Dynamics
Drivers
- Rising prevalence of Extramammary Paget disease
The surging prevalence of Extramammary Paget
disease is a major factor driving the market's growth rate during the forecast
period of 2022-2029. A pluripotent keratinocyte stem cell, Taker cell, or
apocrine gland duct cell could be the cell of origin in primary extramammary
Paget disease.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the
growth rate of Extramammary Paget disease market is the rising healthcare
expenditure which helps in improving its infrastructure. Also, various
government organizations aim to improve the healthcare infrastructure by
increasing funding and this will further influence the market dynamics.
Opportunities
- Increase in the number of research and development
activities
The market's growth is fuelled by an
increase in the number of research and development activities. This will
provide beneficial opportunities for the Extramammary Paget disease market
growth.
Restraints/Challenges
On the other hand, high cost associated with
the available treatment and diagnosis will obstruct the growth rate of the
market. The lack of healthcare infrastructure in developing economies and
dearth of skilled professionals will challenge the Extramammary Paget disease
market.
Patient
Epidemiology Analysis
EMPD is a rare disease, with just a few
hundred instances described in the medical literature worldwide. The exact
frequency is unknown. EMPD accounts for 6.5 percent of all cutaneous Paget
disease cases and primarily affects patients aged 50 to 80, with a peak age of
65.3 years.
Get sample report here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-extramammary-paget-disease-market
Market Definition
Extramammary
Paget disease (EPMD) is an uncommon condition characterized by a chronic skin
rash in the vaginal areas that looks like eczema. Needle biopsy or ultrasound
screening of regional lymph nodes are needed tests, as is the search for other
malignancies using procedures such as colonoscopy, cervical smear, or
mammography.
Global Extramammary
Paget Disease Market Scope
The Extramammary Paget disease market is
segmented on the basis of type, route of administration, diagnosis, treatment,
end-users and distribution channel. Type 1
- Type 2
- Type 3
Route of Administration
- Oral
- Topical
- Parenteral
- Others
Diagnosis
- Needle Biopsy
- Ultrasound
- Colonoscopy
- Cervical Smear
- Mammography
Treatment
- Surgery
- Cryotherapy
- Mohs micrographic surgery
- Excisional biopsy
- Vulvectomy
- Radiation Therapy
- Aminolaevulinic Acid Based
Photodynamic Therapy
- Laser Ablation
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Competitive
Landscape and Extramammary Paget Disease Market Share Analysis
The Extramammary Paget disease market
competitive landscape provides details by competitor. Details included are
company overview, company financials, revenue generated, market potential,
investment in research and development, new market initiatives, global
presence, production sites and facilities, production capacities, company
strengths and weaknesses, product launch, product width and breadth,
application dominance. The above data points provided are only related to the
companies' focus related to Extramammary Paget disease market.
Some of the major players operating in the
Extramammary Paget disease market are:
- F.
Hoffmann-La Roche Ltd. (Switzerland)
- Mylan
N.V. (U.S.)
- Teva
Pharmaceutical Industries Ltd. (Ireland)
- Sanofi
(France)
- Pfizer
Inc. (U.S.)
- GlaxoSmithKline
plc (U.K.)
- Novartis
AG (Switzerland)
- Merck
& Co., Inc. (U.S.)
- Allergan
(Ireland)
- AstraZeneca
(U.K.)
- Johnson
& Johnson Private Limited (U.S.)
- Hikmah
Pharmaceuticals PLC (U.K.)
- Bristol-Myers
Squibb Company (U.S.)
- Bayer
AG (Germany)
- Boehringer
Ingelheim International GmbH. (Germany)
- Rd.
Reddy’s Laboratories Ltd. (India)
- Gilead
Sciences, Inc. (U.S.)
- Amgen
Inc. (U.S.)
- Eli
Lilly and Company (U.S.)
- AbbVie
Inc. (U.S.)
- Lupin
(India)
- Allergan
(Ireland)
Get toc
of report https://www.databridgemarketresearch.com/toc/?dbmr=global-extramammary-paget-disease-market
MAJOR
TOC OF THE REPORT
Ø Chapter
One: Introduction
Ø Chapter
Two: Market Dynamics
Ø Chapter
Three: Market Definition
Ø Chapter
Four: Market Scope
Ø Chapter
Five: Market Share Analysis
Get Full Access Report https://www.databridgemarketresearch.com/reports/global-extramammary-paget-disease-market
Browse Related Reports
Global Women's Health Market – Industry Trends and Forecast
to 2029
Global Smart Healthcare Market – Industry Trends
and Forecast to 2029
Global Contract Research Organization (CROs) Services Market – Industry
Trends and Forecast to 2029
About Us:
Data
Bridge Market Research set forth itself as an unconventional and neoteric
Market research and consulting firm with unparalleled level of resilience and
integrated approaches. We are determined to unearth the best market
opportunities and foster efficient information for your business to thrive in
the market
Contact:
Data Bridge
Market Research
Tel:
+1-888-387-2818
Comments
Post a Comment